FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

washington, D.C. 203

OMB APPROVAL		
OMB Number:	3235-028	

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 2. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person Myovant Sciences Ltd. [MYOV] SVF Investments (UK) Ltd Director X 10% Owner Officer (give title Other (specify 3. Date of Earliest Transaction (Month/Day/Year) below) below) (Last) (First) (Middle) 04/02/2018 **69 GROSVENOR STREET** 6. Individual or Joint/Group Filing (Check Applicable Line) 4. If Amendment, Date of Original Filed (Month/Day/Year) (Street) Form filed by One Reporting Person LONDON X0W1K 3JP Form filed by More than One Reporting (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 5. Amount of 6. Ownership 7. Nature of Indirect Transaction Execution Date. Securities Form: Direct Beneficial Ownership (Month/Day/Year) Code (Instr. 8) (D) or Indirect (I) if any Beneficially (Instr. 4) Owned (Month/Day/Year) Following (Instr. 4) Reported (A) or (D) Transaction(s) Code Amount Price (Instr. 3 and 4) See Common Shares 04/02/2018 1.110.015(1)(2)(3) \$20.27 38,341,357 Α Explanation(1)(2)(3) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of 3. Transaction 3A. Deemed 5. Number 6. Date Exercisable and 7. Title and 8. Price of 9. Number of 11. Nature Ownership Conversion Transaction Derivative Execution Date **Expiration Date** Amount of Derivative derivative of Indirect (Month/Day/Year) Security or Exercise Price of if any (Month/Day/Year) Code (Instr. 8) Derivative (Month/Day/Year) Securities Security (Instr. 5) Securities Form: Direct (D) Beneficial Ownership (Instr. 3) Underlying Beneficially Securities Derivative Acquired Derivative Owned or Indirect (Instr. 4) (A) or Disposed Following Security (Instr. 3 (I) (Instr. 4) Security and 4) Reported of (D) (Instr. 3, 4 Transaction(s) (Instr. 4) and 5) Amount Number Date **Expiration** (D) Title Shares (A)

1		l .		-	_	
				Code	v	
1. Name and Address of Reporting Person* SVF Investments (UK) Ltd						
(Last)	SVENOR S	(First) FREET	(Middle)			
(Street)	N	X0	W1K 3JP			
(City)		(State)	(Zip)			
Name and Address of Reporting Person* SoftBank Vision Fund L.P.						
(Last)	SVENOR S	(First) FREET	(Middle)			
(Street)	N	X0	W1K 3JP			
(City)		(State)	(Zip)			
Name and Address of Reporting Person* SVF Holdings (UK) LLP						
(Last)	SVENOR S	(First) TREET	(Middle)			

(Street) LONDON	X0	W1K 3JP		
(City)	(State)	(Zip)		
1. Name and Address of Reporting Person* <u>SVF GP (Jersey) Ltd</u>				
(Last) AZTEC GROUP F		(Middle)		
(Street) ST. HELIER	Y9	JE4 0QH		
(City)	(State)	(Zip)		

Explanation of Responses:

- 1. The Reporting Persons (as defined below) do not directly own any common shares (the "Common Shares") of Myovant Sciences Ltd. (the "Issuer"). The Reporting Persons acquired Roivant Sciences Ltd. ("Roivant") common shares on September 6, 2017. Roivant directly holds the 38,341,357 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the "Roivant Board"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant.
- 2. The Roivant common shares are held directly by SVF Investments (UK) Limited ("SVF Investments"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP ("SVF Holdings"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. ("SoftBank Vision Fund"). SVF GP (Jersey) Limited ("SVF GP"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the "Reporting Persons". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings.
- 3. The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Remarks

Exhibit 24.1 - Power of Attorney (incorporated by reference to Form 3 filed by the Reporting Persons on September 14, 2017)

 Karen Ubell, Attorney-in-Fact
 04/04/2018

 Karen Ubell, Attorney-in-Fact
 04/04/2018

 Karen Ubell, Attorney-in-Fact
 04/04/2018

 Karen Ubell, Attorney-in-Fact
 04/04/2018

 *** Signature of Reporting Person
 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.